已收盤 07-18 16:00:00 美东时间
-0.243
-0.31%
Fate Therapeutics granted 30,000 stock options with a $1.12 exercise price and 37,900 RSUs to new employees on July 2, 2025, under its equity plan. These grants were approved by the Compensation Committee as inducements for employment. Options and RSUs vest over four years, with 25% vesting annually and the remainder in monthly installments, contingent on continuous employment.
07-03 17:05
Canada is ramping up economic pressure on the U.S. with a fresh ultimatum as trade tensions escalate over steel and aluminum tariffs.
06-20 10:44